SEARCH RESULT

Total Matching Records found : 835

Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of Cancer known as chronic myeloid leukaemia (CML). The...

More »

HIV, Cancer patients seek access to affordable medicines-Aarti Dhar

-The Hindu     Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, Cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...

More »

New mechanism: price of Cancer drugs set to fall -Himani Chandna Gurtoo

-The Hindustan Times Cancer drugs will cost almost 25% less if the regulator implements a new formula that calls for a price cap. The price regulator National Pharmaceutical Pricing Authority (NPPA) is considering a pricing mechanism similar to the one for insulin products - which has brought down prices by up to 40% - for 33 Cancer drugs, most of them generics. Basically, the lowest price from the list of drugs in a...

More »

Most big patented drugs skip India -Rupali Mukherjee

-The Times of India Big pharma may be crying hoarse over India's "weak'' intellectual property environment, but over the past five years or so, they have introduced only a handful of their patented blockbusters in the country. That's not all. The contribution of patented drugs in the Rs 72,000-crore pharma retail market is not even 1%, indicating that multinationals have been traditionally slow and have a poor track record in introducing...

More »

More battles in store-Aarti Dhar

-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of Cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast Cancer, which affects about one in four patients with the disease. Rough...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close